The profound influence of microbiota in cancer initiation and progression has been under
the spotlight for years, leading to numerous researches on cancer microbiome entering …

The intestinal microbiota determines immune responses against extraintestinal antigens,
including tumor-associated antigens. Indeed, depletion or gross perturbation of the …

Recent discoveries in commensal microbiota demonstrate the great promise of intratumoral
bacteria as attractive molecular targets of tumors in improving cancer treatment. However …

Implant‐associated infections (IAIs) are the main cause of prosthetic implant failure.
Bacterial biofilms prevent antibiotic penetration, and the unique metabolic conditions in …

Activation of the cyclic GMP‐AMP synthase‐stimulator of interferon genes (cGAS‐STING)
pathway has emerged as an efficient strategy to improve the therapeutic outcomes of …

The intestinal and intratumoral microbiota are closely associated with tumor progression and
response to antitumor treatments. The antibacterial or tumor microenvironment (TME) …

The microbiome has emerged as a significant biomarker and modulator in cancer
development and treatment response. Recent research highlights the notable role of …

Recent advancements in genomics, transcriptomics, and metabolomics have significantly
advanced our understanding of the human gut microbiome and its impact on the efficacy …

Chemoimmunotherapy is an emerging paradigm in the clinic for treating several malignant
diseases, such as non-small cell lung cancer, breast cancer, and large B-cell lymphoma …

Necroptotic immunogenic cell death (ICD) can activate the human immune system to treat
the metastasis and recurrence of triple-negative breast cancer (TNBC). However …